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Drug compounding is an important part of the healthcare system 
and affords patients access to custom prescription medications that best 
fit their individualized needs.1  There are a variety of reasons why 
certain standardized Food and Drug Administration (“FDA”) approved 
drugs may need to be modified for specific patients, including a change 
in dosage, concentration, method of delivery, or to accommodate certain 
allergies.2  To best fit these needs, drugs may be compounded by 
pharmacists in special compounding pharmacies, or even by physicians 
in their offices.3  Interestingly, the regulations governing these 
compounding processes are very different.4  The FDA articulated several 
broad guidelines to direct the compounding of medications in general, 
but state organizations enforce their own compounding regulations.5  A 
state’s board of pharmacy typically creates regulations to govern 
compounding in pharmacies; however, compounding done by 
physicians in their offices is much less regulated, if at all.6  State 
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	 1	 See	Compounding	and	the	FDA:	Questions	and	Answers, U.S. FOOD AND DRUG ADMIN.,	
https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-
questions-and-answers [hereinafter Compounding	and	the	FDA] (last updated June 21, 
2018); Pew Charitable Trusts et al., State	Oversight	of	Drug	Compounding, 4 (Feb. 2018), 
https://www.pewtrusts.org/media/assets/2018/02/drug_safety_assesment_web.pdf 
[hereinafter State	Oversight]. 
	 2	 Compounding	and	the	FDA,	supra note 1; See	generally State	Oversight,	supra	note 
1.  
	 3	 State	Oversight, supra	note 1, at 1. 
	 4	 See	generally State	Oversight,	supra	note 1. 
	 5	 See	State	Oversight,	supra	note 1, at 4-5, 16; Joanne S. Eglovitch, The	FDA	Aims	To	
Strike	Balance	On	Inspecting	Physicians	Who	Compound, PINK SHEET (Aug. 8, 2019).  
	 6	 National	 Reports	 Raise	 Questions	 About	 Oversight	 of	 Drug	 Compounding	 in	
Physicians’	Offices, 46 NEWSL. OF THE NAT. ASSOC. OF BDS. OF PHARMACY 3, 6-7 (Mar. 2017), 
https://nabp.pharmacy/wp-
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pharmacy boards do not have jurisdiction over physicians and the 
board’s regulations regarding medical compounding do not reach far 
enough to cover physicians.7  Additionally, state medical boards govern 
a physician’s practice, but rarely enact or enforce any regulations 
regarding drug compounding.8  This legislative gap recently came to 
light when numerous public health crises arose relating to drug 
compounding.9  These crises brought legislators and regulatory bodies 
together to establish more stringent regulations to create safer products 
for the consumer.10  In order for New Jersey to safeguard its residents 
while still providing efficient access to the customized medications 
residents need, state legislators must make changes to the compounding 
regulatory process done inside physicians’ offices.   
Part II of this comment will examine the history of drug 
compounding, the benefits and risks associated with compounded 
medications, and the current status of regulations regarding 
compounding both in New Jersey and across the country.  Part II will 
also detail the meningitis crisis of 2012 which highlighted the dangers 
of drug compounding and pushed regulators across the country to make 
a change to drug compounding regulations.11  Part III of this comment 
will outline the different pathways New Jersey can take to change 
regulations regarding physician in-office compounding to promote a 
more perfect balance between efficiency of care and safety of patients.  
Part III begins with an analysis of the new regulations in Ohio, which 
were promulgated in 2017,12 and then considers current FDA and 
United States Pharmacopeia (“USP”) concerns.  This comment will argue 
New Jersey would be best served by a new legislative and regulatory 
approach guided by the principles in the Ohio regulations.  This new 
approach should stimulate the use of the more heavily regulated 503B 




	 7	 National	Reports	Raise	Questions,	supra	note 6, at 6.	 
	 8	 National	Reports	Raise	Questions,	supra	note 6, at 6, 7. 
 9 Stacey L. Worthy, The	Compounding	Conundrum:	How	Insufficient	Delineation	of	
Regulatory	Responsibility	Has	Created	a	Need	for	State	and	Federal	Compounding	Drug	
Law	Reform, 72 FOOD DRUG L. J. 506, 521 (2017).  
	 10	 State	Oversight,	supra	note 1, at 4.  
	 11	 State	Oversight,	supra	note 1, at 4. 
 12 OHIO REV. CODE. ANN. § 4729.541(c)-(d) (LexisNexis 2017); Terminal	Distributor	
Requirements	 for	 Prescribers	 Possessing	 Compounded	 Drugs	 or	 Engaging	 in	 Drug	




DIGORI  (DO NOT DELETE) 2/2/2021  9:18 AM 
2021]	 COMMENT 213 
and by incentivizing their usage through tax breaks.13  In addition to 
these regulatory measures, to best serve New Jersey and its residents, 
this comment will also propose that New Jersey should create a hybrid 
committee comprised of members from both the New Jersey Board of 
Pharmacy and the New Jersey Board of Medical Examiners.  This 
dynamic group, after intense collaborative research, can erect a 
comprehensive and effective set of regulations for physicians who 
choose to compound medications for patients in their own offices.  Part 
IV of the comment will conclude with the different proposals outlined 
throughout the comment and once again highlight the need for and 
importance of this regulation.   
II. BACKGROUND 
A. What	is	a	Compounded	Medication?	
Today, large pharmaceutical companies manufacture mass 
quantities of most medications available to consumers in the United 
States.14  Physicians or other healthcare providers prescribe these 
drugs, and then pharmacists in traditional pharmacies dispense the 
drugs to patients.15  In contrast to manufactured medications, 
compounded medications are modified drugs that physicians or 
pharmacists make in small doses specifically for an individual patient.16  
The USP, the only independent, nongovernmental pharmacopeia17 in 
the world, defines compounding as “the preparation, mixing, 
assembling, altering, packaging, and labeling of a drug, drug-delivery 
device, or device in accordance with a licensed practitioner’s 
prescription . . . based on the 
practitioner/patient/pharmacist/compounder relationship in the 
course of professional practice.”18  Stated more simply, a physician or a 
 
	 13	 See	 generally	 infra note 52 (delineating the facilities that fall under 503A 
regulations.). 
 14 Burt’s – Medicine, Understanding	 the	 Difference	 Between	 Compounding	 and	
Pharmaceutical	 Manufacturing, BURT’S RX (Jan. 6, 2018), 
https://burtsrx.com/difference-compounding-pharmaceutical-manufacturing/. 
	 15	 See	id.  
	 16	 Id. 
 17 A pharmacopeia is a collection of uniform pharmaceutical standards comprised 
of requirements regarding the quality of medicinal products, the substances used to 
manufacture them, and quality control methods; See	generally	J. Mark Wiggins & Joseph 
A. Albanese, A	 Brief	History	 of	 Pharmacopoeias:	A	Global	 Perspective, BIOPHARM INT’L 
(Sept. 15, 2019).   
	 18	 Frequently	Asked	Questions	About	Pharmaceutical	Compounding, AM. PHARMACISTS 
ASS’N, https://www.pharmacist.com/frequently-asked-questions-about-
pharmaceutical-compounding [hereinafter Frequently	Asked	Questions] (last visited 
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pharmacist mixes and prepares compounded medications for a certain 
individual based on a prescription from a physician when no FDA-
approved medication fits a patient’s precise needs.19  Often described as 
both an art and a science, this process allows patients to obtain 
individualized care tailored specifically to them.20   
Specific needs that can be served by a compounded medication 
include changes in dosage or method of delivery as well as changes to 
accommodate certain allergies.21  Changes in dosage and method of 
delivery are most common when physicians treat children, the elderly, 
and patients with other special healthcare needs.22  For example, many 
children are unable to swallow oral tablet medications; this poses 
problems if a physician decides the child requires a medication that is 
only commercially manufactured in an oral tablet form.23  However, 
drug compounding addresses this issue by allowing pharmacists or 
physicians to mix the same active ingredients of the oral tablet into a 
liquid or suppository in order for the child to ingest the medication.24  
This process may also be used for the elderly who may be unable or 
unwilling to take oral capsule medications.25   
Additionally, compounded medications provide a unique solution 
for patients with various allergies.26  Mass manufactured drugs are 
created to cause reactions in as few people as possible; however, there 
are some medications that include various allergens like lactose, gluten, 
or certain dyes.27  Compounding allows for a pharmacist or physician to 
 
Jan. 16, 2021). See	also	Review	of	World	Pharmacopoeias 3 (WHO, Working Document 
QAS/12.512/Rev.1 (Mar. 2013), 
https://www.who.int/medicines/areas/quality_safety/quality_assurance/resources/I
nternationalMeetingWorldPharmacopoeias_QAS13-512Rev1_25032013.pdf (defining 
a pharmacopoeia as “a legally binding collection, prepared by a national or regional 
authority, of standards and quality specifications for medicines used in that country or 
region.”). 
	 19	 Frequently	Asked	Questions,	supra	note 18. 
	 20	 Frequently	Asked	Questions,	supra	note 18. 
	 21	 Compounding	and	the	FDA,	supra	note 1. 
	 22	 See Tricia Heitman, A. J. Day & August S. Bassani, Pediatric	Compounding	
Pharmacy:	Taking	on	the	Responsibility	of	Providing	Quality	Customized	Prescriptions, 
CHILDREN (BASEL) 1, 5 (May 4, 2019), https://www.ncbi.nlm.nih.gov /pmc/articles/ 
PMC6560512/. 
	 23	 Id. at 1. 
	 24	 Id.  
	 25	 Compounding	and	the	FDA, supra note 1.  
 26 Burt’s – Compounding Six	 Medical	 Situations	 That	 Call	 for	 Compounded	
Medications, BURT’S RX (July 21, 2017), https://burtsrx.com/6-medical-situations-
compounded-medications/. 
	 27	 Patients	with	Allergies	Look	to	Compounding	Pharmacies	for	Medication, ARENA 
DISTRICT PHARM. (Nov. 25, 2017), https://www.arenadistrictpharmacycolumbus.com/ 
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create an individualized version of that medication by either removing 
the additive and leaving only the active, essential ingredients; they can 
also add an antihistamine to the drug in order to combat an allergy.28  
Without compounding, these patients would not be able to get the 
medications they need, or, if the medication was particularly 
indispensable to their health, the patient would have to suffer the 
adverse consequences due to their allergy.29   
Compounded medications are created when the exact strength of a 
drug “may not be commercially available” or when a patient needs “a 
drug that is currently in shortage” or when such drug has been 
discontinued for whatever reason.30  In addition to the uses above, 
compounded medications are also used to treat hormone-related 
conditions, pain, and skin issues.31  Most prescriptions for compounded 
medications come from dermatologists, pain specialists, 
endocrinologists, and gastroenterologists.32  There have been 
significant increases in the dermatological compounds such as sprays, 
gels, foams, and ointments.33  Usually pharmacists, or dermatologists 
themselves, compound these gels to contain one or more anesthetic, 
analgesic, sedative, antidepressant, anti-seizure or muscle relaxant 
drugs that are used to treat pain.34   
 
blog/26848/Patients-with-Allergies-Look-to-Compounding-Pharmacies-for-
Medication/ [hereinafter Patients	with	Allergies]. 
	 28	 Id.	 
	 29	 Id.  
	 30	 Frequently	Asked	Questions,	supra	note 18. 
 31 Ronilee Shye, What	Are	Compounded	Medications?, GOODRX (last visited Jan. 16, 
2021), https://www.goodrx.com/blog/what-are-compounded-medications/. 
 32 Aamir Hussain & Diana Bolotin, The	Drug	Compounding	Debate	and	its	Importance	
to	Dermatologists,  
DERMATOLOGIST (last visited Jan. 16, 2021), https://www.the-
dermatologist.com/article/drug-compounding-debate-and-its-importance-
dermatologists; Ronilee Shye, What	Are	Compounded	Medications?, GOODRX (last visited 
Dec. 12, 2020), https://www.goodrx.com/blog/what-are-compounded-medications/.  
	 33	 Compounding	Pharmacies	Market	 to	Hit	$14	Billion	by	2026, PR NEWSWIRE (last 
visited Dec. 12, 2020), https://www.prnewswire.com/news-releases/compounding-
pharmacies-market-to-hit-14-billion-by-2026-global-market-insights-inc-
301073406.html; See	also Research	Pushes	Back	on	Benefits	of	Compounded	Topical	Pain	
Creams, JOHNS HOPKINS MED. (Feb. 5, 2019), 
https://www.hopkinsmedicine.org/news/newsroom/news-releases/research-
pushes-back-on-benefits-of-compounded-topical-pain-creams. 
	 34	 Research	 Pushes	 Back	 on	 Benefits	 of	 Compounded	 Topical	 Pain	 Creams, JOHNS 
HOPKINS MED. (Feb. 5, 2019), 
https://www.hopkinsmedicine.org/news/newsroom/news-releases/research-
pushes-back-on-benefits-of-compounded-topical-pain-creams; However, there is a 
growing body of research that suggests these topical creams have no scientific benefit, 
and are not nearly as effective as the oral equivalents of these medications. This 
comment will not discuss the effectiveness of these drugs and will instead focus on their 
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It is important to note that the FDA itself does not regulate the 
approval process of compounded drugs.35  The FDA seeks control over 
compounded medications by enacting federal regulations that must be 
enforced by state regulatory agencies.36  Although FDA regulations 
surround and attempt to regulate compounded drugs, these drugs are 
not subject to the same quality assurance standards as are mass-
manufactured medications.37   
B. Who	Can	Compound	Medications?	
Those engaged in human drug compounding can be divided into 
two distinct categories: traditional and non-traditional compounders.38  
Traditional compounders consist of pharmacists and physicians.39  The 
most common compounding is done by licensed pharmacists in 
compounding pharmacies.40  Currently, about 7,500 compounding 
pharmacies in the United States specialize in advanced compounding 
services.41  Of these compounding pharmacies, approximately 3,000 of 
them produce sterile products that must be made under stricter 
standards than non-sterile products.42  Injections or infusions 
traditionally use sterile compounds.43  Typically suspensions, 
ointments, creams, or capsules use non-sterile products.44  In addition 
to pharmacists, physicians may also compound drugs in their offices.45  
The scope of physician in-office compounding is quite unknown and the 
National Association of Boards of Pharmacy has opined that the number 
 
prevalence in the field. This comment will also address how this practice factors into 
physician in-office compounding and will highlight the need for new regulations.  
	 35	 Compounding	and	the	FDA,	supra	note 1; This point will be explained in greater 
detail below.  
	 36	 See Compounding	and	the	FDA, supra	note 1. 
	 37	 Compounding	and	the	FDA,	supra	note 1.  
	 38	 See State	Regulation	of	Compounding	Pharmacies, NAT’L CONF. OF STATE LEGS. (Oct. 
1, 2014), http://www.ncsl.org/research/health/regulating-compounding-
pharmacies.aspx; see	also Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013-
2014).  
	 39	 Frequently	Asked	Questions,	supra	note 18. 
	 40	 Frequently	Asked	Questions,	supra	note 18. 
 41 Daniel J. DeNoon, What	Are	Compounding	Pharmacies?	Meningitis	Outbreak	From	
Compounded	 Drug	 Raises	 Questions	 Over	 Pharmacies, WEBMD (Oct. 10, 2012), 
https://www.webmd.com/brain/news/20121010/what-are-compounding-
pharmacies#1. 
	 42	 Id.  
	 43	 Sterile	vs	Non‐Sterile	Compounding	Pharmacies, RENUE PHARMACY (last visited Oct. 
3, 2020) https://renuerx.com/sterile-vs-non-sterile-compounding-pharmacies/.  
	 44	 Id.  
	 45	 National	Reports	Raise	Questions,	supra	note 6. 
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of physician-compounders varies widely by specialty.46  Physicians who 
are general practitioners may perform no in-office compounding, while 
other more specialized physicians (like allergists and dermatologists) 
may treat hundreds of patients with compounded medication.47  
Specialists like allergists, dermatologists, immunologists, oncologists, 
ophthalmologists and rheumatologists are most likely to engage in in-
office compounding, and therefore, are most likely to be affected by any 
new compounding regulations.48   
In 2013, through the Drug Quality and Security Act (“DQSA”), 
Congress created a new regulatory category of drugs compounders 
called “outsourcing facilities.”49  DQSA established a new section of the 
Federal Food, Drug, and Cosmetic Act (“FDCA”), Section 503B, that set 
forth regulations for these facilities to compound drugs in compliance 
with the FDA.50  The FDA categorizes these facilities as being non-
traditional compounders because their drugs need only be compounded 
under the supervision of a licensed pharmacist.51  Additionally, 
outsourcing facilities are able to produce large batches of popular, 
compounded drugs with or without a prescription to be sold to 
healthcare facilities because those drugs are non-patient specific.52  
Drugs compounded by facilities in compliance with 503B qualify for 
exemptions from some FDA approval requirements, including drug 
approval processes, labeling requirements, and supply chain tracking 
requirements.53  However, this registration does not excuse outsourcing 
facilities from current good manufacturing process (“CGMP”) 
requirements.54  Outsourcing facilities registered with the FDA are also 
subject to inspection by the FDA according to a risk-based schedule and 
must also report to the FDA adverse events that occur at the facility.55   
 
	 46	 National	Reports	Raise	Questions,	supra	note 6. 
	 47	 National	Reports	Raise	Questions,	supra	note 6. 
	 48	 National	Reports	Raise	Questions,	supra	note 6. 
	 49	 Center	 for	Drug	Evaluation	and	Research:	Outsourcing	Facility	 Information, U.S. 
FOOD AND DRUG ADMIN. 2 (Sept. 2017), http://www.fda.gov/media/107569/download. 
	 50	 Id.  
	 51	 Id.  
	 52	 Compounding	Pharmacies:	Understanding	503A	vs.	503B	Designations	and	Why	It	
Matters, WELLS PHARMACY NETWORK (last visited Oct. 3, 2020), 
http://www.wellsrx.com/503a-vs-503b-compounding-pharmacies/ [hereinafter 
Understanding	503A	vs.	503B].  
	 53	 Id.; Joanna Shepherd, Regulatory	 Gaps	 in	 Drug	 Compounding:	 Implications	 for	
Patient	Safety,	Innovation,	and	Fraud, 68 DEPAUL L. REV. 385, 396 (2019).  
	 54	 Understanding	503A	vs.	503B, supra	note 52. 
	 55	 Center	 for	Drug	Evaluation	and	Research:	Outsourcing	Facility	 Information, U.S. 
FOOD AND DRUG ADMIN. 4 (Sept. 2017), http://www.fda.gov/media/107569/download. 
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C. What	are	the	Benefits	and	Risks	Associated	with	
Compounded	Medications?	
Compounding drugs has been a cornerstone of the pharmaceutical 
and medical professions since their ancient beginnings.56  In the 1930s, 
approximately 60% of all medications were compounded by 
pharmacists.57  As times changed and major pharmaceutical companies 
in the United States began mass producing most medications, the art of 
compounding steeply declined.58  In the mid-twentieth century, 
pharmacists moved from being the makers of medicine to mere 
dispensers of mass-produced products.59  But as the twentieth century 
progressed, medical professionals have revived the compounding 
movement, realizing the benefits that custom medications afford their 
patients.60  In 2019 alone, the drug compounding industry had an 
estimated U.S. market size of $8.9 billion.61   
Custom compounded medications provide patients with a variety 
of benefits they cannot obtain by mass-produced pharmaceuticals.  One 
of the most important, and most interesting, benefits is that 
compounded medications can allow patients access to medications that 
large pharmaceutical manufacturers have discontinued.62  Patients who 
still need this discontinued medication can receive it through 
compounding, where a pharmacist or physician can recreate the 
medication using pharmaceutical ingredients and the latest research.63  
This process allows patients who need vital medicines to receive them 
continuously, regardless of the pharmaceutical industry’s red tape.  
Additionally, compounded medications allow patients with allergies to 
obtain the benefits of the medication without the unwanted side 
effects.64  For example, if a patient is allergic to dyes, gluten, or lactose, 
a physician or pharmacist could make the medication without the 
offensive ingredient.  This practice allows patients the ability to take 
 
	 56	 History	 and	 Evolution	 of	 Compounding, MEDISCA (last visited Dec. 12, 2020), 
https://www.medisca.com/compounding/history-and-evolution.  
	 57	 Frequently	 Asked	 Questions	 about	 Pharmaceutical	 Compounding, Doug’s 
Compounding Pharmacy (last visited Dec. 12, 2020), https://www.dougsrx.com/faq/.  
	 58	 History	 and	 Evolution	 of	 Compounding, MEDISCA (2019), 
https://www.medisca.com/compounding/history-and-evolution. 
	 59	 Id.  
	 60	 Id.  
 61 Greg Levine, Joshua Oyster & Rebecca Williams, Outsourcing	Facilities	Face	Rising	
Drug	 Compounding	 Risks, LAW 360 (Sept. 18, 2019), 
https://www.law360.com/articles/1199983/outsourcing-facilities-face-rising-drug-
compounding-risks.  
	 62	 Frequently	Asked	Questions, supra	note 18. 
	 63	 Frequently	Asked	Questions, supra	note 18. 
	 64	 Frequently	Asked	Questions,	supra	note 18. 
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necessary medications without the sometimes painful and bothersome 
side effects.65  Customized compounded medications also allow for 
changes in dosage and method of delivery in order to benefit specific 
patients like children and the elderly, as previously described above.66   
While there certainly are benefits to compounded medications, 
there are a variety of risks associated with them.67  The FDA approves 
and controls drugs manufactured by pharmaceutical companies and 
dispensed by pharmacists.68  The Center for Drug Evaluation and 
Research (“CDER”), a branch of the FDA, evaluates all new drugs before 
they become available for use by consumers.69  The CDER drug approval 
process requires a team of highly-trained physicians, chemists, and 
pharmacologists to evaluate the clinical testing performed on a 
particular drug.70  Simply put, this in-depth analysis assesses how a 
medication seeks to treat a particular illness and ensures that the 
intended benefits of the medication outweigh the potential risks.71  A 
stamp of approval from CDER, and subsequently the FDA, allows 
physicians and their patients peace of mind in knowing that the 
prescribed medication is effective and safe for use.72   
As stated before, the FDA itself does not regulate the approval 
process of compounded medications.73  Therefore, the FDA cannot 
verify the safety, effectiveness, and quality of compounded medications 
as it does with manufactured drugs.74  Although the FDA has regulations 
in place and frequently issues guidance documents regarding 
compounded medications, the lesser oversight subjects consumers to a 
heightened risk of unsafe formulations.  For example, “[i]n 2001 and in 
2006, FDA investigators found that [thirty percent] of compounded 
drug samples they tested contained either too little or too much of the 
active ingredient.”75  Additionally, unlike the flurry of regulations and 
 
	 65	 Patients	with	Allergies, supra	note 27.	 
 66 Heitman,	supra	note 22. 
 67 Jennifer Gudeman et. al, Potential	Risks	of	Pharmacy	Compounding, 13 DRUGS IN 
R&D 1, 1-8 (Mar. 23, 2013), https://link.springer.com/article/10.1007%2Fs40268-
013-0005-9. 
	 68	 Development	 and	 Approval	 Process, U.S. FOOD & DRUG ADMIN. (2019), 
https://www.fda.gov/drugs/development-approval-process-drugs. 
	 69	 Id.  
	 70	 Id.  
	 71	 Id.  
	 72	 Id.  
	 73	 Compounding	and	the	FDA, supra	note 1. 
	 74	 Compounding	and	the	FDA, supra	note 1. 
 75 Catherine Staes et. al., Description	of	Outbreaks	of	Healthcare	Associated	Infections	
Related	to	Compounding	Pharmacies	2000‐2012, AM. J. HEALTH SYS. PHARM (Aug. 1, 2014), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886339/. 
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testing performed on manufactured medications, there are fewer safety 
regulations regarding compounded medications.  For example, there are 
currently no state regulations that require pharmacists or physicians to 
have specialized drug compounding training.76  It is concerning that 
individuals tasked with mixing individualized medications are not 
required to have any additional training regarding the drugs or the 
compounding preparation.  Lastly, because the FDA does not approve or 
regulate compounded drugs, they do not require compounders to report 
adverse events.77  This is particularly concerning because the FDA, and 
consequently consumers, may never know of potentially serious issues 
that exist in compounding pharmacies or physicians’ offices.   
The most important illustration of these risks came in October 
2012 when the United States experienced a serious fungal meningitis 
outbreak that occurred as the result of contaminated compounded 
drugs.78  Contaminated injectable methylprednisolone, a type of steroid 
injection manufactured by New England Compounding Center (“NECC”) 
in Framingham, Massachusetts, caused this outbreak.79  This 
contaminated compounded drug affected patients in over nineteen 
states across the country.80  Estimates suggest that this single 
compounding pharmacy put over thirteen thousand people at risk.81  
The Center for Disease Control and Prevention (“CDC”) reports that over 
750 patients developed serious illnesses including meningitis, stroke, 
joint infections, and other central nervous system infections.  Sixty-four 
of those patients died as a result of their injuries.82  Additionally, those 
who survived the incident still suffer consequences, enduring years of 
medical treatments and devastating pain.83   
Although this outbreak is the most well-known incident, 
compounded drugs caused eleven other infectious incidents between 
2000 and 2012.84  These prior cases involved 207 patient injuries 
 
	 76	 Frequently	Asked	Questions,	supra	note 18.  
	 77	 Compounding	and	the	FDA, supra	note 1. 
 78 Staes, supra	note 75, at 2.  
 79 Staes, supra	note 75, at 2. 
 80 Staes, supra	note 75, at 2. 
 81 DeNoon, supra note 41.  
	 82	 How	the	NECC	Case	Changed	Compounding	Pharmacy, MJH LIFE SCIENCES (June 14, 
2017), [hereinafter NECC], https://www.drugtopics.com/latest/how-necc-case-
changed-compounding-pharmacy; Sydney Lupkin, 5	Things	We	Didn’t	Know	About	the	
Fungal	 Outbreak	 Last	 Year, ABC NEWS (last visited Jan. 16, 2020), 
https://abcnews.go.com/Health/things-fungal-outbreak-year/story?id=20661674.  
	 83	 Id. 
 84 Staes, supra	note 75 at 1. 
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resulting in seventeen deaths85 and an overall fatality rate of 8.2%.86  
Including the 2012 outbreak, thirteen different drugs produced at 
twelve different compounding pharmacies in ten different states caused 
these incidents.87  Additionally, authorities only discovered ten of the 
outbreaks after a “cluster of case-patients from a common hospital or 
clinic presented with similar clinical characteristics to a common 
setting.”88  This means that compounding pharmacies, free from 
requirements to report adverse events like outbreaks, could have been 
distributing dangerous contaminated drugs for an extended period of 
time.89  Lastly, an investigation into one of these compounding facilities, 
performed only after several patients fell ill, found a second 
contaminated drug with the potential to harm the public.90   
D. Who	Regulates	Drug	Compounding?	
The regulations surrounding drug compounding are complex in 
nature, come from a variety of sources, and lack clarity.91  Although all 
compounded drugs pose the same risks, different regulations apply to 
compounding performed in different settings.92  According to the FDA, 
“quality requirements for compounded drugs differ depending on the 
setting where compounding occurs.”93  Additionally, because the 
regulations vary so much, they are particularly hard to enforce, creating 
more potential for harm to consumers.94  Although the FDA does not 
follow a strict approval process for compounded drugs in the same way 
that they do manufactured drugs, it still has set standards.95  State 
regulatory agencies, whose practices can vary widely from state to state, 
then enforce these federal regulations.96  This section will summarize 
the regulations.   
 
 85 Staes, supra	note 75, at 1. 
 86 Staes, supra	note 75, at 1. 
 87 Staes, supra	note 75, at 8-9. 
 88 Staes, supra	note 75, at 9. 
	 89	 See generally Staes,	supra	note	75. 
 90 Staes, supra	note 75, at 10. 
	 91	 Compounding	Confusion:	Uncertainty	Swirls	 in	Compound	Pharmacy	Regulation, 
QUARLES & BRADY, LLP (Aug. 7, 2017), https://www.quarles.com/news/compounding-
confusion-uncertainty-swirls-in-compound-pharmacy-regulation/.   
	 92	 Id. 
	 93	 Compounding	and	the	FDA, supra	note 1, at 3. 
	 94	 Compounding	and	the	FDA, supra	note 1, at 3. 
	 95	 Compounding	and	the	FDA, supra	note 1, at 2-3. 
	 96	 See State	Regulation	of	Compounding	Pharmacies, supra note 38.  
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1. Federal Regulations  
In November of 2013, Congress passed bipartisan legislation called 
the Drug Quality and Security Act (DQSA), which sought to create more 
oversight and accountability in the making of compounded 
medications.97  This legislation was a direct response to the 2012 
meningitis outbreak that resulted from unsafe compounded 
medications.98  DQSA clearly identified the two types of compounders—
”traditional” and “non-traditional” compounders.99  Traditional 
compounders are pharmacies or physicians who prepare medications 
in light of a specific patient’s needs via an individual prescription.100  
Section 503A of the FDCA governs these compounders.101  Non-
traditional compounders, enumerated for the first time in the DQSA, are 
known as outsourcing facilities.102  Essentially, these facilities are 
companies who produce inventory of commonly compounded drugs, 
created without a patient-specific prescription, and sell them to 
physicians for office use.103  Section 503B of the FDCA governs these 
outsourcing facilities.104  The FDA solely regulates these facilities and 
these facilities are not subject to the same state-level regulations as 
traditional compounders, as will be explained below.105   
The Food and Drug Administration Modernization Act of 1997 
added Section 503A to the FDCA.106  Section 503A sets forth the 
conditions that must be satisfied for drug products compounded by a 
licensed pharmacist or physician in order to be exempt from the 
following three sections of the FDCA.107  Compounding pharmacies do 
not have to comply with: (1) Section 501(a)(2)(B) concerning current 
good manufacturing practice; (2) Section 502(f)(1) concerning the 
labeling of drugs with adequate directions for use; and (3) Section 505 
concerning the approval of drugs under new drug applications.108   
 
 97 Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013-2014).  
	 98	 See	Compounding	Laws	and	Policies, U.S. FOOD AND DRUG ADMIN.	(last visited Dec.12, 
2020), https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-
and-policies.  
 99 Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013-2014). 
	 100	 Id.; See Frequently	Asked	Questions,	supra	note 18. 
	 101	 See Frequently	Asked	Questions,	supra	note 18. 
 102 H.R. 3204. 
	 103	 Id.  
	 104	 Id.  
	 105	 Id. 
	 106	 Pharmacy	 Compounding	 of	 Human	 Drug	 Products	 Under	 Section	 503A	 of	 the	
Federal	 Food,	 Drug,	 and	 Cosmetic	 Act, U.S. FOOD AND DRUG ADMIN. (June 2016), 
https://www.fda.gov/media/94393/download. 
	 107	 Id. 
	 108	 Id.  
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In contrast,  Section 503B governs outsourcing facilities that 
compound medications that are sold to healthcare facilities for in-office 
use.109  The FDA is the sole regulator of these outsourcing facilities; thus, 
all outsourcing facilities are required to register with the FDA.110  
Section 503B also requires that these outsourcing facilities comply with 
USP Sections 795 and 797, as well as with the CGMP.111  This extra 
compliance with the CGMP makes the standards stricter under Section 
503B than for compounding pharmacies under Section 503A.112  
Additionally, these regulations force outsourcing facilities to follow 
DQSA labeling requirements while compounding pharmacies under 
Section 503A are not required to follow these same regulations.  Hence, 
drugs compounded at outsourcing facilities under more regulations will 
likely have higher indicia of safety than those compounded at traditional 
facilities regulated under Section 503A.   
Since the deadly meningitis outbreak in 2012, the FDA has 
provided numerous guidance documents, including priorities plans 
highlighting their drug compounding initiatives.113  In 2018, the FDA 
shared a Compounding Priorities Plan that emphasized the 
administration’s key priorities for the coming years.114  In its 2018 
regulations, the FDA stated that one of its goals was having more 
compounding pharmacies register as 503B facilities because they are 
subject to higher quality standards and better oversight than any other 
compounding facility.115   
2. State Regulations 
At the same time that federal regulations were being debated to 
ensure that a public health crisis similar to the meningitis outbreak 
would not occur again, many states began to re-examine their drug 
compounding regulations.  Although the specific duties and functions 
may vary slightly from state to state, each state has a collection of 
professional regulatory boards that serve the public by governing the 
licensing and practicing of individuals within a particular occupation.116  
 
	 109	 See Understanding	503A	vs.	503B, supra	note 52.	 
	 110	 See Understanding	503A	vs.	503B, supra	note 52. 
	 111	 Understanding	503A	vs.	503B,	supra	note 52. 
	 112	 See Understanding	503A	vs.	503B,	supra	note 52. 
	 113	 See	e.g.,	Compounding	and	the	FDA,	supra	note 1. 
	 114	 2018	 Compounding	 Priorities	 Plan, U.S. FOOD AND DRUG ADMIN. (June 21, 2018), 
https://www.fda.gov/drugs/human-drug-compounding/2018-compounding-policy-
priorities-plan.  
	 115	 Id.	 
	 116	 See id.; See What	is	the	Role	of	the	Regulatory	Board	in	Credentialing	Programs?, 
PROFESSIONAL TESTING, INC. (2006), 
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A regulatory board is usually comprised of various members of the 
profession as well as members of the general public who have a 
significant interest in the functioning of the board.117  These boards 
create and enforce detailed licensing requirements which help 
safeguard the public by ensuring that the individuals in a specific 
profession have the necessary education and training.118  Additionally, 
these boards ensure that the licensed professionals act in compliance 
with the specific rules and regulations put in place by that board.119  
Most boards have a detailed disciplinary process should they find, 
usually via a complaint process, that a member is not acting in 
accordance with their regulations.120  The board has the power to 
suspend, revoke, or deny licensure to an individual who it deems 
noncompliant with its regulations.121   
State pharmacy boards are responsible for licensing pharmacists 
practicing within their state.122  More specifically, they are responsible 
for enforcing regulations regarding compounding done by pharmacists 
in pharmacies.123  While the FDA oversees pharmaceutical 
manufacturing, each state has their own specific regulations regarding 
compounding and their own enforcement procedures.  New Jersey’s 
specific requirements are codified in the regulations and contain 
standards for pharmacy compounding including storage, 
recordkeeping, and safety protocols.124   
In contrast, state medical boards are responsible for the licensing 
and regulating of physicians within a particular state.125  Their main goal 
is to assure the public that the physicians licensed in their state are, not 




	 117	 See	e.g.,	Board Members, The New Jersey Board of Pharmacy (last visited Jan. 16, 
2019), https://www.njconsumeraffairs.gov/phar/Pages/members.aspx. 
	 118	 See Role	of	the	Regulatory	Board,	supra	note 116.	 
	 119	 See	Role	of	the	Regulatory	Board,	supra	note 116. 
	 120	 See	Role	of	the	Regulatory	Board,	supra	note 116; see	also Ike Devji, What	You	Need	
To	 Know	 About	 Medical	 Board	 Complaints, PHYSICIAN’S PRACTICE (Aug. 28, 2019), 
https://www.physicianspractice.com/view/what-you-need-know-about-medical-
board-complaints. 
	 121	 See Role	of	the	Regulatory	Board,	supra	note 116;	see	also Ike Devji, What	You	Need	
To	 Know	 About	 Medical	 Board	 Complaints, PHYSICIAN’S PRACTICE (Aug. 28, 2019), 
https://www.physicianspractice.com/view/what-you-need-know-about-medical-
board-complaints 
	 122	 See State	Regulation	of	Compounding	Pharmacies, supra	note 38. 
	 123	 See State	Regulation	of	Compounding	Pharmacies, supra	note 38. 
	 124	 See State	Regulation	of	Compounding	Pharmacies, supra	note 38. 	
	 125	 See Role	of	the	Regulatory	Board, supra	note 116. 
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care.126  Because the compounding of drugs can be performed by both 
pharmacists and physicians alike, quality and safety control falls 
directly upon these two regulating bodies and can often get lost in the 
shuffle.  While it is clear that boards of pharmacy have control over 
pharmacists who compound drugs, they do not always have jurisdiction 
over physicians who do so.127   
Additionally, state medical boards are usually complaint-driven 
agencies.128  This means that the board does not typically inspect or 
examine a doctor’s office until a patient has filed a complaint against 
them.129  Therefore, unsafe and hazardous compounding conditions are 
only found after a patient suffers harm.  This could create a dangerous 
situation if a physician is compounding a large quantity of unsafe drugs.  
The situation will only come to light and be remedied once an injured or 
aggrieved party files a complaint with the board, which could ultimately 
be too late.   
In New Jersey, the Board of Pharmacy governs compounding done 
by pharmacists in the state and sets out specific regulations that must 
be followed in these compounding pharmacies.130  The state medical 
board is silent, however, on regulating physician compounding.131  
Therefore, only professional standards set by the profession itself 
regulate physicians who compound in New Jersey.132   
III. ANALYSIS 
A. Ohio	as	a	Test	State	for	Implementing	Stricter	Regulations	
In order to decide what will best serve New Jersey, this comment 
will first analyze the changes that were made to compounding 
regulations in other states like Ohio.  Then, this comment will propose a 
pathway that New Jersey regulators can adopt in moving forward with 
stricter regulations on physician in-office compounding.  The strongest, 
 
	 126	 See Role	of	the	Regulatory	Board, supra	note 116. 
 127 Rebecca Burke, Physician	Compounding	Comes	Under	Scrutiny, AHLA WEEKLY 
(Jun. 1, 2018), https://www.powerslaw.com/wp-content/ uploads/ 2018/06/ 
Weekly_Burke.pdf.  
 128 John W. Rusher, How	To	Prevent,	Respond	To	A	Complaint	To	State	Medical	Board, 
APP NEWS (last visited Jan. 16, 2020), 
https://www.aappublications.org/news/2018/03/02/law030218.  
	 129	 Id.	 
 130 N.J. ADMIN. CODE § 13:39-11 (2020); These specific regulations will not be 
discussed in detail as they do not apply to physicians compounding in their offices. 
These regulations are standard and in compliance with the FDA and USP standards for 
compounding after 2013.  
 131 N.J. STAT. ANN. § 45:9 et seq.  
	 132	 Id. 
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and most important argument will be that New Jersey should implement 
stricter regulations on physicians that force them to take advantage of 
503B outsourcing facilities.  In doing so, residents will maintain access 
to compounded drugs, and rest assured they are created in the safest 
environments with the strictest regulations.   
Ohio was one of the first states to pioneer changes to state-level 
regulations involving drug compounding after federal-level changes to 
the industry in 2013.133  Currently, Ohio has the strictest drug 
compounding laws in the country; it serves as the prototype for other 
states as they contemplate changes to their own drug compounding 
regulations.134  In order to better oversee the process of drug 
compounding in the most effective way, the Ohio Board of Pharmacy 
oversees all compounding done by traditional compounders, including 
physicians.135   
As of April 1, 2017, the Ohio Board of Pharmacy requires that all 
prescribers who possess compounded drugs obtain a license as a 
terminal distributor of dangerous drugs (“TDDD”).136  Additionally, 
those who engage in the compounding of dangerous drugs (i.e. 
prescription drugs), must obtain this TDDD license as well.137  After 
April 1, 2017, any facility possessing compounded drugs or engaging in 
the compounding of drugs without complying with the TDDD licensing 
requirements violates Ohio law.138  The TDDD licensing requirements 
includes the completion of “a 17-page form, an annual $160.00 fee, and 
an agreement to have the premises inspected at any time without 
notice.”139   
 
	 133	 See	 Brett Coldiron, The	 Compounding	 Struggle	 Continues, MD EDGE (Oct. 23, 
2018), https://www.mdedge.com/dermatology/article/177795/business-
medicine/compounding-struggle-continues-write-now-help-your. 
	 134	 See id.  
	 135	 See	National	Reports	Raise	Questions, supra	note 7 at 8.  
 136 OHIO REV. CODE. ANN. § 4729.541(c)-(d) (LexisNexis 2017); Terminal	Distributor	
Requirements	 for	 Prescribers	 Possessing	 Compounded	 Drugs	 or	 Engaging	 in	 Drug	




	 137	 Id. 
	 138	 Terminal	Distributor	Requirements	for	Prescribers	Possessing	Compounded	Drugs	




 139 Elizabeth Muennich & Brett Coldiron, Barriers	 to	 Compounding	 in	 Physician	
Offices:	 The	 Future	 Is	 Now, J. AM ACAD. DERMATOLOGY (Mar. 2019), 
https://www.jaad.org/action/showPdf?pii=S0190-9622%2818%2932581-7.  
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The new regulations define compounding broadly to encompass 
almost any mixing of two or more prescription drugs; the regulations 
also do not differentiate between sterile and non-sterile medications.140  
Additionally, the regulations provide that compounded drugs used 
within six hours of preparation must be prepared in a designated, clean 
“medication area” by authorized personnel with proper hand 
hygiene.141  Compounded drugs that are used more than six hours after 
being prepared require a designated “clean room” with environmental 
control devices and additional equipment which is limited to authorized 
personnel whom have had additional training.142   
B. Proposals	for	New	Jersey	
1. Using Ohio as a Guidepost for Flexible Regulations 
and Incentivizing Outsourcing Facilities 
Physicians in Ohio have had negative reactions and strongly 
oppose the new regulations that were put in place in 2017.143  It is 
important for New Jersey to recognize the Ohio medical communities’ 
feedback, and work to find a balance that works favorably for physicians 
and consumers.  Such attention should be paid because it will be crucial 
to use Ohio’s regulations as a guidepost for designing New Jersey 
regulations going forward.   
The main complaint from physicians regarding Ohio’s regulations 
is that they believe requiring all compounders to acquire a TDDD is too 
strict.144  Additionally, physicians claim that the standards attached to 
the TDDD license are unduly restrictive and unnecessary.  These 
standards also impose serious financial burdens on the physicians.145  
New Jersey could certainly come up with a different licensing 
 
	 140	 See	OHIO REV. CODE ANN. § 4729.01(c) (LexisNexis 2017).  
	 141	 See	 Terminal	 Distributor	 Requirements	 for	 Prescribers	 Possessing	 Compounded	




	 142	 Id.; Cost	 of	 a	 Cleanroom	 per	 Square	 Foot, MERCART CLEANROOMS, 
https://www.mecart-cleanrooms.com/cost-cleanroom-per-square-foot/.	Necessitating 
a “clean room” space would require physician compounders to create an entirely new 
space where physicians could compound medications in line with the standards 
promulgated in Ohio, which could be incredibly expensive. Clean rooms, for example, 
may need to include certain ventilation systems, air pressure systems, fume hoods, and 
separate areas for personnel to dress in gowns and other protective equipment. The cost 
of implementing one of these rooms can range from $100 - $1000 per square foot.  
	 143	 See	Coldiron, supra	note 133.  
	 144	 See	Coldiron, supra note 133.  
	 145	 See	Coldiron, supra	note 133133. 
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requirement for compounding physicians that is less strict than a TDDD 
license.  It is in the best interests of the State to create an entirely new 
licensing process for physicians altogether since there are little to no 
regulation in this area of the law.  Working with a hybrid committee, as 
explained below, could allow regulators and physicians to come up with 
an option that is less burdensome while still acting to protect patients 
from potentially dangerous drugs.  An intense study of the Ohio rules, as 
well as a collaborative effort involving all interested parties, would 
certainly make for the most efficient outcome.  However, the result of 
this process must increase safety for consumers of physician 
compounded drugs in New Jersey.   
One of the most innovative programs regarding compounding 
regulations has been the creation of outsourcing facilities that are 
regulated under Section 503B.146  As previously stated, these facilities 
are able to produce mass quantities of commonly compounded drugs 
without patient-specific prescriptions.147  These compounded 
medications are then sold to physicians and other healthcare facilities 
for in-office use.148  The outsourcing facilities are regulated under 
stricter rules than Section 503A facilities because they must comply 
with CGMP in addition to other USP regulations.149  These facilities are 
required to register with the FDA, in addition to the state’s Boards of 
Pharmacy, so they are subject to risk-based inspections by the FDA.150  
All of these additional regulations indicate that drugs produced at these 
facilities are likely to be safer for the consumer—the explicit goal the 
FDA expressed in both its 2018 and 2019 compounding guidance 
documents.151   
New Jersey should incentivize the creation of outsourcing facilities 
in our state because of the benefits mentioned above, including lower 
risk to patients who use compounded medications.  If New Jersey were 
to adopt strict standards for compounding that are similar to Ohio’s, 
physicians who use compounded medications to treat their patients 
regularly, but not enough to necessitate compliance with tedious TDDD 
requirements, would likely outsource their compounding needs.  By 
forcing physician compounders to either comply with stricter 
regulations or utilize 503B outsourcing facilities, compounded drugs 
will inevitably be subject to more regulations and, thus will be safer for 
 
 146 Shepherd, supra	note 53, at 395-96.	 
	 147	 Understanding	503A	vs.	503B, supra	note 52. 
	 148	 Understanding	503A	vs.	503B,	supra	note 52. 
	 149	 Understanding	503A	vs.	503B, supra	note 52. 
	 150	 2018	Compounding	Priorities	Plan, supra note 114, at 1.  
	 151	 2018	Compounding	Priorities	Plan, supra note 114, at 1-3. 
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consumers.  Incentives like tax breaks or tax exemptions would 
stimulate the creation of outsourcing facilities in New Jersey.152  
Additionally, bringing these facilities into the state would create more 
jobs and help to stimulate New Jersey’s economy.153   
2. Giving the State Board of Pharmacy Jurisdiction Over 
Physicians 
New Jersey can help close the gap in legislation regarding 
compounding pharmacies and physician in-office compounding by 
granting the New Jersey Board of Pharmacy jurisdiction over physicians 
who compound in their offices.  Although this would create more work 
for the New Jersey Board of Pharmacy, it would also create regulations 
for the direct oversight of physicians who compound in their offices.  
Ohio did this in 2017 and it has been met with some opposition, but that 
controversy stems from the strictness of the regulations, not the fact 
that the Ohio Board of Pharmacy has jurisdiction over physician in-
office compounding.   
3. Creating a Hybrid Committee  
Another important step that would help close the regulatory gap 
between compounding pharmacies and physician in-office 
compounding includes New Jersey establishing a hybrid committee 
consisting of members of the New Jersey Board of Pharmacy and the 
New Jersey Board of Medical Examiners.  The committee could also, if 
deemed necessary, include outside members of both professions who 
have a significant interest in the regulations of compounding in general 
as well as physician in-office compounding.  This committee would 
mainly serve an advisory role that would help guide regulatory changes 
of compounded medications.  Regulatory boards often form outside 
committees in order to investigate in-depth issues that will affect the 
board and all of its licensees.  It is important that concerns surrounding 
compounded medications be debated in the most collaborative way 
possible in order to establish regulations that work for pharmacists, 
physicians, and most importantly, the consumers.   
Creating or changing regulations and legislation is a notoriously 
lengthy process that necessitates careful consideration.  For example, it 
took almost a full year after the 2012 meningitis outbreak for new 
 
 152 Carl Davis, Tax	Incentives:	Costly	for	States,	Drag	on	the	Nation, INST. ON TAX’N AND 
ECON. POL’Y (Aug. 12, 2013), https://itep.org/wp-
content/uploads/taxincentiveeffectiveness.pdf.  
	 153	 See	id.  
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federal statutes to be passed regarding human drug compounding.154  
Even today, seven years later, there is still a great amount of work to be 
done.  The hybrid committee, while not a perfect solution, would allow 
an intense and necessary discussion of the issues surrounding physician 
compounding and could educate the New Jersey Legislature and other 
regulatory bodies who will ultimately have the final say in what the next 
steps will be for New Jersey.  Additionally, both regulatory boards have 
an important stake in the issue and would benefit from working 
together to efficiently establish guideposts in order to protect consumer 
health.  There can never be too much dialogue surrounding an 
important issue, especially one that affects the health of so many New 
Jersey residents.   
C. Counterarguments	
The potential for new restrictions on in-office compounding has 
already been widely contested by physicians.155  Physicians claim that 
new FDA guidance requiring their facilities to comply with the same 
standards as compounding pharmacies would limit their ability to 
provide vital care to their patients.156  Some physicians argue that 
stricter restrictions would severely limit a physician’s ability to prepare 
sterile drug products to administer to patients.157  Physicians claim that 
the reduced access to care will increase risks for patients because there 
will be fewer facilities providing theses sterile drugs.158  Additionally, 
doctors claim that it would be extremely difficult for them to retrofit 
their offices with the new equipment and “clean rooms” that Ohio’s 
guidance requires.159  In order to comply with the potential 
requirements, such as implementing designated clean rooms or a vent 
hood, some offices would be required to make structural changes or find 
new spaces to operate.160  Lastly, physicians argue that there is little to 
no evidence demonstrating a significant patient risk to necessitate a 
massive overhaul of the current in-office compounding system.161   
 
	 154	 2018	Compounding	Priorities	Plan, supra note 114, at 1. 
 155 Brett Coldiron, How	To	Explain	Physician	Compounding	to	Legis., MD EDGE (June 
19, 2017), https://www.mdedge.com/dermatology/article/140696/business-
medicine/how-explain-physician-compounding-legislators. 
 156 Coldiron, supra	note 133.  
	 157	 See	Coldiron, supra	note 133. 
 158 Coldiron, supra	note 133. 
	 159	 See	Coldiron, supra	note 133. 
	 160	 See	Coldiron, supra	note 133. 
 161 Coldiron, supra	note 133. 
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Dermatologists in Ohio have been some of the strongest voices in 
opposition to this strict regulation.162  In an article urging 
dermatologists and physicians nationwide to oppose such regulations, 
the executives of Ohio Dermatological Association state that they are 
“astounded by the intrusiveness of the Pharmacy board [sic].”163  They 
go on to analyze the rules as applied to dermatology, stating that “mixing 
any prescription drug into another vehicle, such as a liquid gel, or 
ointment, for topical use is compounding” and “[w]hen you are 
compounding a prescription, you are compounding a dangerous 
drug.”164   
Recently, dermatologists in Ohio have attempted to outline how 
outrageous the TDDD licensing requirement is.165  Whilst urging other 
dermatologists and compounding physicians across the country to 
persuade their local legislators that the restrictive Ohio compounding 
laws should not be enacted in other states, dermatologist Brett Coldiron 
created a demonstration that he believes illustrates the unnecessary 
restrictiveness of these regulations.166  He suggests when a doctor 
quickly mixes epinephrine and bicarbonate in a syringe, a simple 
procedure to treat skin cancer patients, will no longer be able to be 
performed in Ohio without a TDDD license.167   
Consumer health, however, should be the utmost priority for all 
healthcare providers, including compounding pharmacists and 
physicians who compound in their offices.  Although stricter 
regulations, surprise office inspections, and additional registration 
materials (such as a TDDD license) may take some initial getting used 
to, it seems to be a small price to pay in order to ensure safer patient 
care.   
The physicians’ main argument is that having fewer physicians to 
provide these vital medications will increase the costs to the consumer.  
This rationale is, at best, flawed.  The new category of outsourcing 
facilities created by the FDA in 2013 could alleviate some of this 
pressure.  These facilities are able to create large quantities of 
commonly compounded drugs and ship them to healthcare facilities 
around the country.168  If the drugs were made in larger quantities and 
 
 162 Muennich,	supra note 139.  
 163 Muennich,	supra note 139 . 
 164 Muennich,	supra note 139. 
	 165	 See	Coldiron, supra	note 155.	 
 166 Coldiron, supra	note 155. 
 167 Coldiron, supra	note 155. 
	 168	 2018	Compounding	Priorities	Plan, supra note 114, at 2. 
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in safer facilities that are regulated directly by the FDA, it would not only 
be safer for the patient but also could lower prices.169   
Additionally, allowing an exemption for physicians who conduct in-
office compounding that permits them to be non-compliant with FDA 
regulations could inevitably create a loophole for compounding 
operations under the guise of a physician170  Creative, profit-oriented 
physicians could potentially circumvent the regulations put in place, 
thereby weakening safeguards for patients across the country.171  A 
loophole could certainly lead to another public health crisis, which could 
be even worse than the 2012 meningitis outbreak that seriously harmed 
thousands of people.172   
IV. CONCLUSION 
Drug compounding is a vital part of the medical landscape that 
provides patients with the ability to obtain custom drugs that fit their 
unique needs.173  Without drug compounding, there are many patients 
who otherwise would be unable to obtain the medications necessary to 
most effectively treat their illnesses.174  But, with all of the benefits 
associated with compounded medications, there are also many risks as 
well.  The 2012 fungal meningitis outbreak sparked a wide range of 
federal and state-wide changes in compounding regulations.  The 
outbreak also highlighted the many problems that existed within the 
field currently, including physician in-office compounding.175  While 
drug compounding will always involve some risk, there are certainly 
ways for New Jersey to minimize them.  It is in the state’s best interest 
to take action to better regulate medical compounding to keep its 
residents safe, especially that which is done in physicians’ offices.   
New Jersey should first look to the Ohio regulations and use them 
as a guidepost for their own regulations.  The Ohio regulations have 
undoubtedly made compounded drugs safer in the state but have also 
faced much criticism from physicians in the state and around the 
country, which should be taken into account as well.  Finding a balance 
between the strict Ohio regulations and the complete lack of regulations 
in New Jersey is possible and crucial to protecting patients while still 
allowing them access to their medications.  New Jersey may also want to 
 
	 169	 See	2018	Compounding	Priorities	Plan, supra note 114, at 3. 
 170 Coldiron, supra	note 155. 
 171 Coldiron, supra	note 155. 
	 172	 NECC, supra	note 82. 
	 173	 Compounding	and	the	FDA,	supra	note 1. 
	 174	 Compounding	and	the	FDA,	supra	note 1. 
	 175	 NECC, supra	note 82 . 
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experiment with other ways that can make compounded drugs safer, 
including creating incentives for Section 503B outsourcing facilities to 
operate in New Jersey.  Forcing compounders into using more heavily 
regulated outsourcing facilities, through stricter regulations for 
physician compounders, will hopefully make drugs safer for the 
consumer.  Additionally, New Jersey should also consider giving the New 
Jersey Board of Pharmacy jurisdiction over compounding physicians as 
well as consider creating a hybrid committee with pharmacists, 
physicians, and other members of the public in order to better 
investigate this issue and all of the various solutions.   
While physician opposition to these measures may be strong at 
first, it is important to remember the backdrop that brought this issue 
to the forefront of medicine in the first place.  The 2012 meningitis 
outbreak significantly affected nearly a thousand people, largely due to 
the lack of regulations regarding compounded drugs.176  The protection 
of the consumer should be the ultimate priority, and by putting stricter 
regulations into effect, New Jersey will accomplish this.   
 
 
 176 Staes, supra	note 75, at 1, 8-9. 
